Project Grant R21AI190691
- The University of North Carolina at Chapel Hill received a $420,553 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research) to develop a single-cell technique that reports the translational rate and transcriptome of individual bacterial cells. The project aims to explore the translational and transcriptomic heterogeneity in Staphylococcus aureus cells during chronic infection and long-term antibiotic treatment,...
- This $421,067 Project Grant was awarded on August 8, 2025 by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant supports research at the University of North Carolina at Chapel Hill to investigate how neutrophil activities contribute to antibiotic treatment failure, particularly for Staphylococcus aureus infections. The research aims to delineate the mechanisms by which neutrophils induce antibiotic...
- This $115,123 federal Project Grant was awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research Program (CFDA 93.855) on Aug 20, 2025. The grant supports research conducted by the University of North Carolina at Chapel Hill (UNC-CH) to investigate strategies for eradicating intracellular Staphylococcus aureus (S. aureus) persisters, which can lead to recurring antibiotic-resistant infections. The key products and services to...
- This $413,542 Project Grant was awarded on August 1, 2025 by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research (CFDA 93.855) federal grant program. The grant supports research aimed at developing novel treatment strategies to limit both intracellular central nervous system (CNS) bacterial burden and glia-driven neuroinflammation. The research team at the University of North Carolina at Charlotte plans to employ a...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $162,000 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of North Carolina at Chapel Hill. The grant supports research to characterize the mechanisms and parameters controlling gene amplification leading to phenotypic heterogeneity in Enterobacter bacteria, which can contribute to antibiotic resistance. The experiments aim to understand how certain Enterobacter...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $233,250 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of North Carolina at Chapel Hill (UNC-CH). The purpose of this 2-year grant, with a start date of May 13, 2025, is to develop a novel platform for delivering therapeutic genetic payloads to targeted bacterial species within complex human microbiomes. Specifically, the research aims to engineer...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $427,625 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of North Carolina at Chapel Hill (UNC-CH). The funding supports research to investigate the causes of treatment failure for liver abscesses caused by hypervirulent Klebsiella pneumoniae infections, which can occur despite appropriate antibiotic therapy. The research aims to use quantitative and imaging mass...
- This federal Project Grant award of $417,845 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to identify novel immune determinants that influence Staphylococcus aureus (S. aureus) biofilm infection. The research will leverage the genetically diverse Collaborative Cross mouse model to better understand how host genetic factors contribute to the heterogeneity observed in immune...
- This Project Grant award of $3,121,542.00 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports the development of animal models and novel positron emission tomography (PET) bioimaging techniques to study Staphylococcus aureus orthopedic implant-associated infections. The research aims to replicate key pathological features of the human disease and enable longitudinal, non-invasive measurements...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $2,937,578 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of North Carolina at Chapel Hill. The grant, awarded on August 18, 2025, will support the development of an ACE2 immunodecoy therapy for long-lasting immunoprophylaxis against SARS-CoV-2 and other zoonotic coronaviruses that target the human ACE2 receptor. The project aims to advance the ACE2-immunodecoy...
The University of North Carolina at Charlotte (UNC Charlotte) was awarded a $402,284 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant, titled "Augmenting Host Innate Immune Responses Against Staphylococcal Osteomyelitis with Antimicrobial Nucleic Acid Structures," aims to develop novel treatment strategies for severe bone infections caused by Staphylococcus aureus. The research will focus on understanding how resident bone cells initiate immune responses and produce antimicrobial agents to combat S. aureus infections, with the goal of enhancing these natural defenses to improve treatment outcomes. The grant period runs from Aug 18, 2025 to Jul 31, 2027.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $402.3k | 8/18/25 |